StockData
Vertex Pharmaceuticals Inc logo

Vertex Pharmaceuticals Inc

VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026Score 15/3036% above fair value
$553.15−5.73 (-1.03%)

Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –

Vertex Pharmaceuticals Level 3 contingent consideration liabilities by Year

Level 3 contingent consideration liabilities — Total fair value ($M) ($M)

QuarterlyAnnual

Vertex Pharmaceuticals Level 3 contingent consideration liabilities: $79M in FY2025, up 2.7% from a year earlier.

Latest, FY2025
79
Period ended Dec 31, 2025
Change on a year earlier
+2.7%
76.9 in FY2024
History
8 years
Since FY2018
Sources
7
Documents cited below

Where the FY2025 figure comes from

Source: Form 10-Q (filed 2026-08-04) ↗

Reported in Form 10-Q / 10-K Fair Value Measurements Note.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedLevel 3 contingent consideration liabilities — Total fair value ($M) ($M)Year on yearSource
FY2025Dec 31, 202579+2.7%Form 10-Q (filed 2026-08-04) ↗
FY2024Dec 31, 202476.9-0.6%Form 10-K (filed 2026-02-13) ↗
FY2023Dec 31, 202377.4-40.0%Form 10-K (filed 2025-02-13) ↗
FY2022Dec 31, 2022129-30.8%Form 10-K (filed 2024-02-15) ↗
FY2021Dec 31, 2021187-1.6%Form 10-K (filed 2023-02-10) ↗
FY2020Dec 31, 2020190+138.2%Form 10-K (filed 2022-02-09) ↗
FY2019Dec 31, 201979.6–Form 10-Q (filed 2026-08-04) ↗
FY2018Dec 31, 20180–Form 10-K (filed 2020-02-13) ↗

Breakdown

What makes up level 3 contingent consideration liabilities

Cite this data

StockData. (2026). Vertex Pharmaceuticals Level 3 contingent consideration liabilities ($M), annual FY2018–FY2025 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/cc-liab-tot

See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.